Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1681903

registered interest
date	15/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the effectiveness of medicinal cannabis treatments provided by the NHS; and whether she has plans to increase the number of treatments available.
tabling member constituency	Romford
tabling member printed	Andrew Rosindell
uin	9453
answer	answer is ministerial correction date of answer 17/01/2024 answer text <p>Licensed cannabis-based medicines are available and funded on the National Health Service, where the safety, quality and clinical and cost effectiveness has been assessed and approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence.</p><p>The Government continues to encourage manufacturers to develop new treatments and invest in research and clinical trials, and offers scientific and research advice from the MHRA and the National Institute for Health and Care Research.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 17/01/2024 17:12:08 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1447 label Biography information for Andrew Rosindell

1663633

registered interest
date	13/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether the Government is taking steps to reduce inequalities in access to medicinal cannabis prescribed under the NHS.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	201487
answer	answer is ministerial correction date of answer 19/10/2023 answer text <p>Licensed cannabis-based medicines are routinely available on the National Health Service. However, clinical guidelines from the National Institute for Health and Care Excellence demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.</p><p>Funding of unlicensed products is subject to local National Health Service decisions on a case-by-case basis. These decisions follow clearly developed procedures that ensure equitable distribution of funding, prioritising those medicines that have proved their safety, quality, and clinical and cost effectiveness.</p><p>We continue to call on manufacturers to conduct research to prove if their products are safe and effective and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.</p> answering member constituency Colchester answering member printed Will Quince question first answered 19/10/2023 14:43:27 answering member 4423 label Biography information for Will Quince
tabling member	4079 label Biography information for Julian Sturdy

1663778

registered interest
date	13/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to increase access to cannabis-based medicinal products on the NHS.
tabling member constituency	Ealing Central and Acton
tabling member printed	Dr Rupa Huq
uin	201631
answer	answer is ministerial correction date of answer 19/10/2023 answer text <p>Licensed cannabis-based medicines are routinely available on the National Health Service. However, clinical guidelines from the National Institute for Health and Care Excellence demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.</p><p>Funding of unlicensed products is subject to local NHS decisions on a case-by-case basis. These decisions follow clearly developed procedures that ensure equitable distribution of funding, prioritising those medicines that have proved their safety, quality and clinical and cost effectiveness.</p><p>We continue to call on manufacturers to conduct research to prove if their products are safe and effective and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.</p> answering member constituency Colchester answering member printed Will Quince question first answered 19/10/2023 11:14:45 answering member 4423 label Biography information for Will Quince
tabling member	4511 label Biography information for Dr Rupa Huq

1652383

registered interest
date	12/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will meet members of the Medcan Family Foundation to discuss the availability of advanced unlicensed medicinal cannabis for those people who had been diagnosed with childhood epilepsy.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	193547
answer	answer is ministerial correction date of answer 17/07/2023 answer text <p>Health Ministers have met with families and patients and have discussed the challenges around the use of unlicensed cannabis-based medicines at great length in Parliament., Ministers are focused on galvanising research to determine if these products are safe and effective and might be funded within the National Health Service.</p><p>The National Institute for Health and Care Research and NHS England will be supporting two world-first randomised control trials on cannabinoids in the treatment of epilepsy. When further details on the trials is available, we will ensure the Medcan Family Foundation are informed.</p> answering member constituency Colchester answering member printed Will Quince question first answered 17/07/2023 14:51:28 answering member 4423 label Biography information for Will Quince
tabling member	242 label Biography information for Sir Christopher Chope

1642217

registered interest
date	06/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure the (a) quality and (b) safety of imported cannabis-based products for medicinal use; if he will make a statement.
tabling member constituency	North Herefordshire
tabling member printed	Sir Bill Wiggin
uin	187907
answer	answer is ministerial correction date of answer 14/06/2023 answer text <p>Cannabis based products for medicinal use in humans (CBPMs) is a term that usually designates medicinal products that are not licensed in the United Kingdom. Most CBPMs in use in the UK are unlicensed medicines imported into the Country. Regulation 167 of the Human Medicine Regulations 2012, as amended, allows for medicines without a marketing authorisation, also referred to as a licence, to be supplied under certain circumstances. In the interest of public health, the exemption is narrowly drawn because unlicensed medicines or specials, unlike licensed medicinal products, have not been assessed by the Licensing Authority against the criteria of safety, quality and efficacy.</p><p>An unlicensed medicine may be supplied following a bona fide unsolicited order and is formulated in accordance with the specific requirements of the prescriber. This means that the quality, safety and efficacy of unlicensed medicines is the direct responsibility of the prescribers responsible for the care of individual patients as they are the ones that determine if these are fit for purpose.</p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) ensures that any importer of an unlicensed medicinal product into the UK must be suitably licensed to import unlicensed medicines and prior to the importation taking place the importer must notify of their intent to import the unlicensed medicine and provide a set of supportive documentation, which the MHRA will assess to ensure the medicine’s quality and safety. This typically includes the requirement that a medicine has been produced in facilities meeting Good Manufacturing Practice or equivalent recognised quality standards for medicines.</p> answering member constituency Colchester answering member printed Will Quince question first answered 14/06/2023 16:50:18 answering member 4423 label Biography information for Will Quince
tabling member	1428 label Biography information for Sir Bill Wiggin

1642219

registered interest
date	06/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of how many people are self-medicating with recreational cannabis for the treatment of chronic illnesses; and if he will make a statement.
tabling member constituency	North Herefordshire
tabling member printed	Sir Bill Wiggin
uin	187909
answer	answer is ministerial correction date of answer 14/06/2023 answer text <p>No estimate has been made. Licensed cannabis-based medicines are routinely available and funded on the National Health Service. However, for unlicensed cannabis-based medicines, clinical guidelines from the National Institute for Health and Care Excellence demonstrate a clear need for more evidence to support routine prescribing and funding decisions.</p><p>We continue to call on manufacturers to conduct research and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.</p> answering member constituency Colchester answering member printed Will Quince question first answered 14/06/2023 16:11:19 answering member 4423 label Biography information for Will Quince
tabling member	1428 label Biography information for Sir Bill Wiggin

1642220

registered interest
date	06/06/2023
answering body	Department for Business and Trade
answering dept id	214
answering dept short name	Business and Trade
answering dept sort name	Business and Trade
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business and Trade, what assessment she has made of the impact of exporting medical cannabis on the UK economy; and if she will make a statement.
tabling member constituency	North Herefordshire
tabling member printed	Sir Bill Wiggin
uin	187910
answer	answer is ministerial correction date of answer 16/06/2023 answer text <p>Life Sciences is one the UK’s top exporting sectors, with exports valued at £28.1 billion in 2022. No assessment has currently been made by the department of the impact of exporting medicinal cannabis on the UK economy. The department supports UK manufacturers of medical cannabis who have obtained a controlled drug licence from the Home Office and relevant licences from MHRA; and where the use of medicinal cannabis is both (a) legal in the destination market and (b) only for medical or scientific purposes. <br></p> answering member constituency Mid Worcestershire answering member printed Nigel Huddleston question first answered 16/06/2023 13:12:20 answering member 4407 label Biography information for Nigel Huddleston
tabling member	1428 label Biography information for Sir Bill Wiggin

1642221

registered interest
date	06/06/2023
answering body	Department for Business and Trade
answering dept id	214
answering dept short name	Business and Trade
answering dept sort name	Business and Trade
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business and Trade, what assessment her Department has made of the growth potential for the cannabinoid-based medicines industry; and if she will make a statement.
tabling member constituency	North Herefordshire
tabling member printed	Sir Bill Wiggin
uin	187911
answer	answer is ministerial correction date of answer 16/06/2023 answer text <p>No assessment has been made on the growth potential for the cannabinoid-based medicine industry which also creates opportunities for the agri-tech sector. The department will continue to deliver against the priority sub-sectors outlined in the Life Science Vision, through our role in pursuing and landing inward investment, enabling exports, attracting global talent and capital, and leading on trade policy and defending free trade.</p> answering member constituency Mid Worcestershire answering member printed Nigel Huddleston question first answered 16/06/2023 13:18:11 answering member 4407 label Biography information for Nigel Huddleston
tabling member	1428 label Biography information for Sir Bill Wiggin

1642222

registered interest
date	06/06/2023
answering body	Department for Business and Trade
answering dept id	214
answering dept short name	Business and Trade
answering dept sort name	Business and Trade
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business and Trade, if she will commission research into the potential benefits to the economy of cannabinoid-based products for medicinal use; and if she will make a statement.
tabling member constituency	North Herefordshire
tabling member printed	Sir Bill Wiggin
uin	187912
answer	answer is ministerial correction date of answer 16/06/2023 answer text <p>The department has no plans to assess the impact of the medical cannabis industry on the economy. Data is annually published on the impact on the economy and employment of the wider Life Sciences sector in the <a href="https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.gov.uk%2Fgovernment%2Fcollections%2Fbioscience-and-health-technology-database-annual-reports&amp;data=05%7C01%7CRobert.Reid%40officeforlifesciences.gov.uk%7C52a0f4af72164a3b141608da90ba3996%7Ccbac700502c143ebb497e6492d1b2dd8%7C0%7C0%7C637981426767702174%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=xG98g%2B1%2BBzW72DAM8Cpp8i%2FEn2ic5G1qf2ZbOzZsXXU%3D&amp;reserved=0" target="_blank">Bioscience and health technology sector statistics</a>. This includes analysis of the bio-pharmaceuticals sector of which the medical cannabis industry is a subsector.</p> answering member constituency Mid Worcestershire answering member printed Nigel Huddleston question first answered 16/06/2023 13:20:04 answering member 4407 label Biography information for Nigel Huddleston
tabling member	1428 label Biography information for Sir Bill Wiggin

1605953

registered interest
date	21/03/2023
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, whether her Department plans to extend Target Pharmacy's licence for Bedrocan products.
tabling member constituency	Inverclyde
tabling member printed	Ronnie Cowan
uin	170649
answer	answer is ministerial correction date of answer 27/03/2023 answer text <p>The Home Office Drug and Firearms Licensing Unit (DFLU) considers applications for premises and company specific controlled drug licences.</p><p>All applications are considered individually and on their merits, after undertaking a physical site visit- if one is needed- and reviewing the evidence submitted to support an application. A prospective licensee may need to demonstrate that product(s) meet the criteria to be considered medicines, and that there is an evidenced need for them. DFLU cannot comment on individual licence applications that may have been made to it.</p><p>The General Pharmaceutical Council (GPhC) is the independent regulator for pharmacists, pharmacy technicians and pharmacy premises in Great Britain.</p> answering member constituency Croydon South answering member printed Chris Philp question first answered 27/03/2023 16:28:25 answering member 4503 label Biography information for Chris Philp
tabling member	4465 label Biography information for Ronnie Cowan